Effects of L-dopa metabolites at a dopamine receptor suggest a basis for 'on-off' effect in Parkinson's disease.
D000818:Animals; D004298:Dopamine / Q000378:metabolism* / Q000494:pharmacology; D018492:Dopamine Antagonists; D005071:Evoked Potentials / Q000187:drug effects; D007413:Intestinal Mucosa / Q000378:metabolism; D007546:Isoquinolines / Q000494:pharmacology*; D007980:Levodopa / Q000627:therapeutic use*; D008974:Mollusca; D009119:Muscle Contraction / Q000187:drug effects; D010208:Papaverine / Q000031:analogs & derivatives* / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy*; D011955:Receptors, Drug; D013237:Stereoisomerism
D018492:Dopamine Antagonists; D007546:Isoquinolines; D011955:Receptors, Drug; D007980:Levodopa; D010208:Papaverine; D004298:Dopamine